<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138124</url>
  </required_header>
  <id_info>
    <org_study_id>114427</org_study_id>
    <secondary_id>EPI40634</secondary_id>
    <secondary_id>WEUSKOP4774</secondary_id>
    <nct_id>NCT01138124</nct_id>
  </id_info>
  <brief_title>Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)</brief_title>
  <official_title>Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there
      has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by
      spontaneous reports in the Adverse Events Reporting System or in the published literature. In
      a published case-control screening study of the association of gabapentin with 55 cancers,
      the only cancer that met the screening criteria for possibly increased cancer risk with
      gabapentin exposure was renal (including renal pelvis) cancer. This association was judged to
      be likely due to or substantially accentuated by confounding by cigarette smoking,
      hypertension, and lifestyle (Cancer Causes Control 2009;20:1821-1835).

      The primary objective of this study is to determine whether exposure to gabapentin is
      associated with an increased risk of developing pancreatic cancer or renal cancer in the
      United Kingdom (UK) General Practice Research Database (GPRD). Almost all members of the UK
      population are registered with a General Practice, which centralizes the medical information
      not only from the general practitioners themselves but also from specialist referrals and
      hospital attendances. Over 487 General Practices contribute data to the GPRD.

      The study cohort from which cases and controls are drawn is all subjects in the GPRD
      1993-2008. Gabapentin was approved in the UK in May 1993. Entry into the study cohort begins
      Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of
      registration if later than Jan 1, 1993. Patients with a first diagnosis of the respective
      cancer 1995-2008 are risk set matched with up to 10 controls within the same General Practice
      for age at cohort entry (within two years), sex, and year of entry into the study cohort
      (within one year). For cases, the index date is the date of first diagnosis of the respective
      cancer. The index date for controls is set as the date at which the follow-up time from
      cohort entry is the same as the case. The index date is chosen so as to give the control
      equal follow-up time to that of the case for ascertainment of use of gabapentin. Cases and
      controls will be required to have at least 2 years of follow-up in the study cohort before
      their index date. Data on gabapentin prescriptions are obtained for cases and controls from
      study cohort entry to the index date.

      Crude and adjusted odds ratios and 95% confidence intervals (CI) will be produced from
      conditional logistic regression models, with additional analyses evaluating for latency and
      dose-response. For pancreatic cancer, covariates are smoking, body mass index, diabetes,
      epilepsy, neuropathic pain, and chronic pancreatitis. For renal cancer, covariates are
      smoking, body mass index, diabetes, hypertension, diuretic use, epilepsy, and neuropathic
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were not recruited for nor enrolled in this study. This study is a retrospective
      observational study. Data from medical records or insurance claims databases are anonymised
      and used to develop a patient cohort. All diagnoses and treatment are recorded in the course
      of routine medical practice. Actual number of patients could be less than , as it is possible
      for a patient to be represented in more than one of the four arms (See &quot;Participant Flow:
      Overall Study&quot; Table) because of the risk set sampling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
    <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</measure>
    <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
    <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
    <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile's with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
    <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile's without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile's with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
    <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</measure>
    <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
    <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
    <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile's with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</measure>
    <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
    <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile's without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile's with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">54202</enrollment>
  <condition>Renal Pelvis Cancer</condition>
  <condition>Restless Legs Syndrome</condition>
  <condition>Epilepsy</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Chronic Pancreatitis</condition>
  <condition>Hypertension</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Diabetes</condition>
  <condition>Renal Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>UK GPRD 1993-2008</arm_group_label>
    <description>The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin prescriptions</intervention_name>
    <description>The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.</description>
    <arm_group_label>UK GPRD 1993-2008</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study cohort from which cases and controls are drawn is all subjects in the UK GPRD
        1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered
        in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
        Follow-up ends Dec 31, 2008, or earlier if the respective cancer is diagnosed, or if the
        subject leaves the GPRD for any reason including death. There are several advantages to the
        GPRD dataset for this study. It is a large dataset with detailed longitudinal prescription
        data, and long term follow-up (mean 7 years) to allow for latency in carcinogenicity. It
        provides good representation of the elderly who are disproportionately affected by
        pancreatic and renal cancers, and routinely includes data recorded by general practitioners
        on potential risk factors such as smoking and body mass index.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The study cohort from which cases and controls are drawn is all subjects in the UK
             GPRD 1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are
             registered in GPRD before that time, and at the time of registration if later than Jan
             1, 1993. Follow-up ends Dec 31, 2008, or earlier if the respective cancer is
             diagnosed, or if the subject leaves the GPRD for any reason including death.

        Exclusion Criteria:

          -  Cases and controls will be required to have at least 2 years of follow-up in the study
             cohort before their index date (For cases, the index date is the date of first
             diagnosis of the respective cancer. The index date for controls is set as the date at
             which the follow-up time from cohort entry is the same as the case.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <results_first_submitted>December 16, 2010</results_first_submitted>
  <results_first_submitted_qc>December 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2011</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal cell carcinoma</keyword>
  <keyword>epidemiology</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>renal cancer</keyword>
  <keyword>renal pelvis cancer</keyword>
  <keyword>GPRD</keyword>
  <keyword>case-control</keyword>
  <keyword>Gapabentin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.</recruitment_details>
      <pre_assignment_details>Actual number of patients may be less, as it is possible for a patient to be represented in more than one of the four arms (See “Participant Flow: Overall Study” Table) because of the risk set sampling.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pancreatic Cancer Cases</title>
          <description>Incident pancreatic cancer, defined as first time pancreatic cancer diagnosis (READ/ Oxford Medical Information System [OXMIS] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident pancreatic cancer diagnosis. Exocrine pancreatic cancer, endocrine pancreatic cancer, and carcinoma in situ were included. Cancer metastatic to the pancreas was excluded.</description>
        </group>
        <group group_id="P2">
          <title>Pancreatic Cancer Controls</title>
          <description>Pancreatic cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site.
The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
        <group group_id="P3">
          <title>Renal Cancer Cases</title>
          <description>Incident renal cancer, defined as first time renal cancer diagnosis (READ/OXMIS codes) in the GPRD study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident renal cancer diagnosis. Renal cell carcinoma and renal pelvis cancer were included; Wilm’s tumor and cancer metastatic to kidney were excluded.</description>
        </group>
        <group group_id="P4">
          <title>Renal Cancer Controls</title>
          <description>Renal cancer cases were risk set matched with up to 10 controls for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3149"/>
                <participants group_id="P2" count="30026"/>
                <participants group_id="P3" count="1981"/>
                <participants group_id="P4" count="19046"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3149"/>
                <participants group_id="P2" count="30026"/>
                <participants group_id="P3" count="1981"/>
                <participants group_id="P4" count="19046"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pancreatic Cancer Cases</title>
          <description>Incident pancreatic cancer, defined as first time pancreatic cancer diagnosis (READ/OXMIS codes) in the GPRD study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident pancreatic cancer diagnosis. Exocrine pancreatic cancer, endocrine pancreatic cancer, and carcinoma in situ were included. Cancer metastatic to the pancreas was excluded.</description>
        </group>
        <group group_id="B2">
          <title>Pancreatic Cancer Controls</title>
          <description>Pancreatic cancer cases were risk set matched with up to 10 controls for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
        <group group_id="B3">
          <title>Renal Cancer Cases</title>
          <description>Incident renal cancer, defined as first time renal cancer diagnosis (READ/OXMIS codes) in the GPRD study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident renal cancer diagnosis. Renal cell carcinoma and renal pelvis cancer were included; Wilm’s tumor and cancer metastatic to kidney were excluded.</description>
        </group>
        <group group_id="B4">
          <title>Renal Cancer Controls</title>
          <description>Renal cancer cases were risk set matched with up to 10 controls for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3149"/>
            <count group_id="B2" value="30026"/>
            <count group_id="B3" value="1981"/>
            <count group_id="B4" value="19046"/>
            <count group_id="B5" value="54202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Number of participants with the indicated age at index date.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="446"/>
                    <measurement group_id="B5" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="897"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="1348"/>
                    <measurement group_id="B5" value="2465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="3616"/>
                    <measurement group_id="B3" value="355"/>
                    <measurement group_id="B4" value="3418"/>
                    <measurement group_id="B5" value="7756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="748"/>
                    <measurement group_id="B2" value="7234"/>
                    <measurement group_id="B3" value="528"/>
                    <measurement group_id="B4" value="5199"/>
                    <measurement group_id="B5" value="13709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1033"/>
                    <measurement group_id="B2" value="10092"/>
                    <measurement group_id="B3" value="594"/>
                    <measurement group_id="B4" value="5604"/>
                    <measurement group_id="B5" value="17323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="897"/>
                    <measurement group_id="B2" value="7988"/>
                    <measurement group_id="B3" value="327"/>
                    <measurement group_id="B4" value="3031"/>
                    <measurement group_id="B5" value="12243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1603"/>
                    <measurement group_id="B2" value="15316"/>
                    <measurement group_id="B3" value="759"/>
                    <measurement group_id="B4" value="7273"/>
                    <measurement group_id="B5" value="24951"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1546"/>
                    <measurement group_id="B2" value="14710"/>
                    <measurement group_id="B3" value="1222"/>
                    <measurement group_id="B4" value="11773"/>
                    <measurement group_id="B5" value="29251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated duration of follow-up from GPRD registration to index date</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="1460"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="1081"/>
                    <measurement group_id="B5" value="2843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="1509"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="1135"/>
                    <measurement group_id="B5" value="2946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-7 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="2007"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="1280"/>
                    <measurement group_id="B5" value="3665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2554"/>
                    <measurement group_id="B2" value="25050"/>
                    <measurement group_id="B3" value="1594"/>
                    <measurement group_id="B4" value="15550"/>
                    <measurement group_id="B5" value="44748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated duration of follow-up from GPRD study cohort entry to ID</title>
          <description>Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date (ID).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="4121"/>
                    <measurement group_id="B3" value="286"/>
                    <measurement group_id="B4" value="2653"/>
                    <measurement group_id="B5" value="7506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="3656"/>
                    <measurement group_id="B3" value="226"/>
                    <measurement group_id="B4" value="2122"/>
                    <measurement group_id="B5" value="6400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-7 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="4213"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="2338"/>
                    <measurement group_id="B5" value="7244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1860"/>
                    <measurement group_id="B2" value="18036"/>
                    <measurement group_id="B3" value="1223"/>
                    <measurement group_id="B4" value="11933"/>
                    <measurement group_id="B5" value="33052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated body mass index (BMI)</title>
          <description>BMI is calculated as weight in kilograms (between one and three years prior to the index date, closest to 1 year prior to index date) divided by height in meters (one year or longer prior to index date) squared (m^2).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18.5 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18.5 to 24.99 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="459"/>
                    <measurement group_id="B2" value="3678"/>
                    <measurement group_id="B3" value="237"/>
                    <measurement group_id="B4" value="2236"/>
                    <measurement group_id="B5" value="6610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 29.99 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="4250"/>
                    <measurement group_id="B3" value="326"/>
                    <measurement group_id="B4" value="2938"/>
                    <measurement group_id="B5" value="7971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="2476"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="1773"/>
                    <measurement group_id="B5" value="4790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1917"/>
                    <measurement group_id="B2" value="19419"/>
                    <measurement group_id="B3" value="1150"/>
                    <measurement group_id="B4" value="11989"/>
                    <measurement group_id="B5" value="34475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated smoking status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="731"/>
                    <measurement group_id="B2" value="4857"/>
                    <measurement group_id="B3" value="476"/>
                    <measurement group_id="B4" value="3555"/>
                    <measurement group_id="B5" value="9619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="768"/>
                    <measurement group_id="B2" value="6626"/>
                    <measurement group_id="B3" value="524"/>
                    <measurement group_id="B4" value="4589"/>
                    <measurement group_id="B5" value="12507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1385"/>
                    <measurement group_id="B2" value="15249"/>
                    <measurement group_id="B3" value="867"/>
                    <measurement group_id="B4" value="9121"/>
                    <measurement group_id="B5" value="26622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Status Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="3294"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="1781"/>
                    <measurement group_id="B5" value="5454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated medical conditions in Pancreatic Cancer Cases/Controls</title>
          <description>Medical conditions up to the index date by READ/OXMIS codes were analyzed.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes (&gt;=2 years prior to index date [ID])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B2" value="2137"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epilepsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="458"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuropathic Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="737"/>
                    <measurement group_id="B2" value="6616"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Pancreatitis (&gt;=2 years prior to ID)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated medical conditions/drug use in Renal Cancer Cases/Controls</title>
          <description>Medical conditions up to the index date by READ/OXMIS codes were analyzed. Drug use up to the index date according to British National Formulary codes was analyzed.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1159"/>
                    <measurement group_id="B4" value="9113"/>
                    <measurement group_id="B5" value="10272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretic use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="875"/>
                    <measurement group_id="B4" value="6396"/>
                    <measurement group_id="B5" value="7271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="240"/>
                    <measurement group_id="B4" value="1598"/>
                    <measurement group_id="B5" value="1838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epilepsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="303"/>
                    <measurement group_id="B5" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuropathic Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="428"/>
                    <measurement group_id="B4" value="4018"/>
                    <measurement group_id="B5" value="4446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</title>
        <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
        <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</title>
          <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3149"/>
                <count group_id="O2" value="30026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ever (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3093"/>
                    <measurement group_id="O2" value="29773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3125"/>
                    <measurement group_id="O2" value="29883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0627</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2183</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</title>
        <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile’s with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
        <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</title>
          <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile’s with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3149"/>
                <count group_id="O2" value="30026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3093"/>
                    <measurement group_id="O2" value="29773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3125"/>
                    <measurement group_id="O2" value="29883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>3.85</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>5.03</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>4.49</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0645</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1232</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3160</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2234</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3071</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6062</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5205</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8042</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</title>
        <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile’s with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
        <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</title>
          <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile’s with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3149"/>
                <count group_id="O2" value="30026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3093"/>
                    <measurement group_id="O2" value="29773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3125"/>
                    <measurement group_id="O2" value="29883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>4.86</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>4.46</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>4.62</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0777</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1762</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6990</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5274</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3245</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6388</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.796</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8772</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</title>
        <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile’s with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
        <time_frame>The case index date (ID) was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</title>
          <description>Incident pancreatic cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile’s with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3149"/>
                <count group_id="O2" value="30026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3093"/>
                    <measurement group_id="O2" value="29773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3125"/>
                    <measurement group_id="O2" value="29883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.88</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0212</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>4.25</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0522</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0337</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0947</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3928</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>3.16</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6502</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3275</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6365</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9858</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7671</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, diabetes, chronic pancreatitis, neuropathic pain, epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</title>
        <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
        <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin</title>
          <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1981"/>
                <count group_id="O2" value="19046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ever (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949"/>
                    <measurement group_id="O2" value="18880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968"/>
                    <measurement group_id="O2" value="18970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0970</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1123</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
            <estimate_desc>Comparison: “Ever (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</title>
        <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile’s with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
        <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions</title>
          <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions),Tertile 2 (3-8 prescriptions), and Tertile 3 (9-218 prescriptions). Tertile’s with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-10 prescriptions),Tertile 3 (11-191 prescriptions).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1981"/>
                <count group_id="O2" value="19046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949"/>
                    <measurement group_id="O2" value="18880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968"/>
                    <measurement group_id="O2" value="18970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>4.44</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>4.14</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0856</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0996</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>5.28</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0563</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0896</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5308</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5458</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>4.02</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7744</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6999</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6528</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6722</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</title>
        <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile’s with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
        <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin</title>
          <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 1.55 months), Tertile 2 (1.56 - 6.44 months), and Tertile 3 (6.45 - 78.36 months). Tertile’s with 2 year lag: Tertile 1 (0.01 - 1.78 months), Tertile 2 (1.79 - 7.20 months), and Tertile 3 (7.21 - 64.13 months).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1981"/>
                <count group_id="O2" value="19046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949"/>
                    <measurement group_id="O2" value="18880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968"/>
                    <measurement group_id="O2" value="18970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>5.28</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>6.25</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0603</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>5.98</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3762</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4073</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9294</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9875</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8110</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3336</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3782</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>4.84</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</title>
        <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile’s with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
        <time_frame>The case index date (ID) was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control ID was the date at which the follow-up time from his/her cohort entry was the same as that for the case.</time_frame>
        <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
        <group_list>
          <group group_id="O1">
            <title>Cases</title>
            <description>Cases</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin</title>
          <description>Incident renal cancer. Gabapentin Exposure Description: Without 2 year lag = Gabapentin exposure from cohort entry to index date. With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Tertile’s without 2 year lag: Tertile 1 (0.01 - 33.6 grams), Tertile 2 (33.7 - 185.0 grams), and Tertile 3 (185.1 - 7500.2 grams). Tertile’s with 2 year lag: Tertile 1 (0.01 - 39.0 grams), Tertile 2 (39.1 - 210.0 grams), and Tertile 3 (210.1 - 5623.8 grams).</description>
          <population>Cases and controls were drawn from the GPRD study cohort. Entry into the study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Follow-up ended Dec 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1981"/>
                <count group_id="O2" value="19046"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1949"/>
                    <measurement group_id="O2" value="18880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (without 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968"/>
                    <measurement group_id="O2" value="18970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 1 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3 (with 2 year lag)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0841</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>3.88</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1313</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1488</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>5.34</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1495</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 1 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>4.22</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2421</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>4.69</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2899</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 2 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9723</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8206</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (without 2 year lag)” and “Never (without 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8135</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Unadjusted Odds Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8173</p_value>
            <method>Conditional Logistic Regression</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
            <estimate_desc>Comparison: “Tertile 3 (with 2 year lag)” and “Never (with 2 year lag)”. Adjusted for smoking, BMI, hypertension, diuretic use, diabetes, neuropathic pain, and epilepsy.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pancreatic Cancer Cases</title>
          <description>Incident pancreatic cancer, defined as first time pancreatic cancer diagnosis (READ/ Oxford Medical Information System [OXMIS] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident pancreatic cancer diagnosis. Exocrine pancreatic cancer, endocrine pancreatic cancer, and carcinoma in situ were included. Cancer metastatic to the pancreas was excluded.</description>
        </group>
        <group group_id="E2">
          <title>Pancreatic Cancer Controls</title>
          <description>Pancreatic cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
        <group group_id="E3">
          <title>Renal Cancer Cases</title>
          <description>Incident renal cancer, defined as first time renal cancer diagnosis (READ/OXMIS codes) in the GPRD study cohort. Entry into the GPRD study cohort began Jan 1, 1993, or at the time of GPRD registration if after Jan 1, 1993. Subjects were required to have at least 2 years of follow-up prior to the index date. The index date for cases was the date of incident renal cancer diagnosis. Renal cell carcinoma and renal pelvis cancer were included; Wilm’s tumor and cancer metastatic to kidney were excluded.</description>
        </group>
        <group group_id="E4">
          <title>Renal Cancer Controls</title>
          <description>Renal cancer cases were risk set matched with up to 10 controls for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

